-- イランの新たな和平提案に対する市場の懐疑的な見方が続く中、原油先物価格は火曜日に3週間ぶりの高値をつけた。 ムルバン原油の期近先物価格は2.5%上昇し1バレル=106.84ドル、ブレント原油先物価格は2.7%上昇し1バレル=111.16ドルとなった。 イランが米国の海上封鎖解除と引き換えにホルムズ海峡の再開を提案したとの報道が出たものの、コメルツ銀行のアナリストは、度重なる失敗を経て市場はこうした報道への信頼を失いつつあると指摘した。 サクソバンクのアナリストは、「米イラン和平交渉は依然として行き詰まり、交渉再開に向けた努力は停滞している。イランは週末、米国に対しホルムズ海峡の再開を提案したと報じられており、ホワイトハウスはトランプ大統領の国家安全保障チームがこの提案を検討していることを確認した」と述べた。 しかし、世界の石油カルテルにとって大きな打撃となる出来事として、アラブ首長国連邦(UAE)は火曜日にOPECとOPECプラスから脱退した。 一方、米国主導の封鎖による物理的な影響はますます深刻化している。 Kplerのデータによると、イランの原油輸出量は70%も激減し、3月の平均185万バレルからわずか56万7000バレルにまで落ち込んだ。 イランの貯蔵施設の残量は22日分未満と推定されており、同国は5月中旬までに最大150万バレルの強制的な減産を余儀なくされる可能性がある。 この供給不足は月曜日、イラン関連の大型タンカー2隻、ティファニ号とフェニックス号が、スリランカ近海で米軍に拿捕された後、封鎖線から逃れるように東へ向かうのが確認されたことで、改めて浮き彫りになった。 RBCキャピタル・マーケッツのストラテジストは、今後の見通しとして、世界の消費者にとって「厳しい夏」となる可能性が高まっていると指摘している。 RBCのアナリストは、3ヶ月目に突入したこの紛争が、原油と石油精製品の供給量を約10億バレルも減少させ、現代史上最大の供給ショックを引き起こしたと警告した。 たとえ外交的な打開策が実現したとしても、インフラと物流への被害が中東の生産回復を極めて遅らせ、需要のピーク期を通して高価格と在庫不足が続くことを専門家は指摘している。
Related Articles
Sector Update: Tech Stocks Fall Late Afternoon
Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.
Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%